๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q)

โœ Scribed by Thomas J. Herzog; Michael W. Sill; Joan L. Walker; David O'Malley; Mark Shahin; Koen DeGeest; Sheldon A. Weiner; David Mutch; Robert L. DeBernardo; Samuel S. Lentz

Book ID
113962684
Publisher
Elsevier Science
Year
2011
Tongue
English
Weight
240 KB
Volume
120
Category
Article
ISSN
0090-8258

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase II evaluation of three-day topotec
Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma : A Gynecologic Oncology Group study
โœ David Scott Miller; John A. Blessing; Samuel S. Lentz; D. Scott McMeekin ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 79 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND Topotecan, administeredintravenously at a dose of 1.5 mg/m^2^ per day for 5 days every 21 days, is an established regimen in the treatment of recurrent ovarian carcinoma. Alternate dosing strategies have sought to improve toxicity. The authors evaluated the tolerability a